FBR Capital Reiterates Outperform on Geron Corp (GERN) Following Disclosed License Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St futures muted as oil tops $100 for first time since July
- Oil nears $100 as fresh Middle East strikes raise supply risks
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Pre-Open Stock Movers 09/19: (ISLE) (BLOX) (TECD) Higher; (VICL) (MGT) (CYH) Lower (more...)
September 19, 2016 9:24 AM EDTIsle of Capri Casinos, Inc. (Nasdaq: ISLE) 31.7% HIGHER; Eldorado Resorts, Inc. (Nasdaq: ERI) and Isle of Capri Casinos, Inc. (Nasdaq: ISLE) announced that they have entered into a definitive merger agreement whereby Eldorado will acquire all of the outstanding shares of Isle of Capri for $23.00 in cash or 1.638 shares of Eldorado common stock, at the election of each Isle of Capri shareholder, reflecting total consideration of approximately $1.7 billion, inclusive of $929 million of long-term debt of Isle of Capri and its... More
Geron Corp (GERN), Janssen Pharma Enter Exclusive Licensing Agreement
September 19, 2016 8:08 AM EDTGeron Corp (Nasdaq: GERN) disclosed the following in a U.S. SEC filing on Monday:
Item 1.01 Entry into a Material Definitive Agreement.
On September 15, 2016 (the Execution Date), Geron Corporation (Geron or the Company) and Janssen Pharmaceuticals, Inc. (Janssen Pharmaceuticals), entered into a license agreement (the License Agreement) granting Janssen Pharmaceuticals exclusive worldwide rights (the Exclusive License) under Gerons proprietary patents and related know-how for the development and commercialization of products based on specialized oligonucleotide backbone chemistry, as well as novel amidates for ribonucleic acid interference, or RNAi, for the prevention, treatment... More
